A Study to Investigate the Effects of Zibotentan/Dapagliflozin Combination Compared to Dapagliflozin Alone in Adult Participants With Chronic Kidney Disease and High Proteinuria

NCT06942910 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

224

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Kidney Disease With High Proteinuria

Interventions

DRUG: Zibotentan/Dapagliflozin
DRUG: Dapagliflozin

Sponsor

AstraZeneca